The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Life-years and quality-adjusted outcomes with belantamab mafodotin in RRMM: DREAMM-7 analysis
Attaya Suvannasankha, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, discusses findings from the Phase III DREAMM-7 (NCT04246047) analysis showing that belantamab mafodotin, bortezomib, and dexamethasone improve life years and quality-adjusted life years compared with other standard regimens in relapsed/refractory multiple myeloma (RRMM). She emphasizes how these results add a patient-centered value perspective to treatment selection beyond efficacy alone. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
